Archives
-
Perospirone: Receptor Pharmacology and Kv1.5 Evidence
2026-10-05
Perospirone, also called SM-9018 free base, combines reported 5-HT2A and D2 receptor antagonism with 5-HT1A partial agonism. A 2025 cellular study additionally reported concentration-dependent inhibition of vascular Kv currents, supporting a research hypothesis about neurovascular pharmacology rather than proving a clinical cardiovascular effect.
-
CRISPRa for Splice-Altering Variants in Fibroblasts
2026-10-05
Terkelsen and colleagues developed a CRISPR activation strategy that induces expression of otherwise inaccessible disease genes in patient-derived skin fibroblasts. The study shows how this approach can support transcript-level analysis of splice-altering variants in MPZ and SPAST, while also defining important boundaries for diagnostic interpretation.
-
EZ Cap™ Cas9 mRNA (m1Ψ): Evidence to Decision
2026-10-04
EZ Cap™ Cas9 mRNA (m1Ψ) combines Cap1 capping, m1Ψ modification, and a poly(A) tail for research in CRISPR-Cas9 genome editing. This article offers an evidence-centered framework that separates molecular design advantages from demonstrated biological outcomes and clarifies the limits of antimicrobial CRISPR evidence.
-
N1-Methylpseudo-UTP: Evidence and Limits
2026-10-03
This source-grounded overview answers five questions about N1-Methyl-Pseudouridine-5'-Triphosphate: its proposed molecular role, what the supplied retrotransposon study actually demonstrates, how strong the evidence is, how to interpret claims about RNA performance, and where applicability ends.
-
Circular RNA CAR-T Therapy for Small Cell Lung Cancer
2026-10-02
Cai et al. developed an electroporation-based circular RNA platform for transient DLL3-targeted CAR-T cells and showed stronger anti-SCLC activity than the corresponding mRNA approach in vitro and in mouse models. The study provides a useful framework for evaluating RNA stability, protein-expression duration, cell engineering, and antitumor function as linked experimental variables.
-
GLT-1, CB1-CREB Signaling, and TBI Cognition
2026-10-01
A 2025 Biomolecules study identifies an astrocyte-centered mechanism connecting post-traumatic 2-AG/CB1 activity with reduced GLT-1, glutamate excitotoxicity, neuronal apoptosis, and cognitive dysfunction. Pharmacological CB1 blockade with AM 281 restored GLT-1 expression and improved behavioral and cellular outcomes in a mouse controlled cortical impact model.
-
AC-Immobilized HRP Activity Measured with Amplex Red
2026-10-01
Prüfer and colleagues established a quantitative fluorescence assay for horseradish peroxidase immobilized by AC dielectrophoresis on titanium nitride nanoelectrode arrays. The study detected as little as 60 fg of HRP and measured up to 45% of the activity expected from an ideal electrode-bound monolayer, supporting DEP as a route toward active enzyme nanoarrays.
-
EZ Cap™ Mouse IL-7 mRNA Guide
2026-09-30
EZ Cap™ Mouse IL-7 mRNA (m1Ψ, HA tag) is an expression reagent designed to produce mouse interleukin-7 while enabling HA-directed detection. Its modified-nucleoside format supports a testable workflow for delivery, translation, and cytokine-response studies, but the supplied dossier does not establish dose, potency, formulation, or in vivo efficacy.
-
N1-Methylpseudouridine for CRISPRa mRNA Workflows
2026-09-30
N1-Methylpseudouridine can support a practical comparison of mRNA chemistries in CRISPR activation assays, where robust dCas9-VPR expression must be separated from splice-specific biology. This guide connects modified-nucleoside handling with fibroblast-based variant analysis, control design, and troubleshooting for reproducible protein expression and RNA readouts.
-
ML-210 and the Radical Logic of Ferroptosis
2026-09-29
A translational framework for using ML-210 to interrogate ferroptosis alongside STING signaling, informed by evidence that H-151 combines STING inhibition with radical-trapping antioxidant activity in renal ischemia-reperfusion injury.
-
Enhanced EZ Cap™ EGFP mRNA: Assay Design
2026-09-29
Enhanced EZ Cap™ EGFP mRNA (m1Ψ) provides a practical reporter framework for dissecting RNA delivery, translation, and nanoparticle performance. This article connects reporter assay design with the programmable potato virus X platform described in recent research.
-
HyperScript™ cDNA for GlmS–sigB Assays
2026-09-28
Discover how the HyperScript First-Strand cDNA Synthesis Kit can support rigorous RNA analysis of the GlmS–sigB regulatory axis in Staphylococcus aureus. This article translates a mechanistic biofilm study into practical decisions about RNA input, primer selection, controls, and qPCR interpretation.
-
2'-O-Methyladenosine: Evidence and Research Use
2026-09-28
2'-O-Methyladenosine is an adenosine nucleoside modified at the ribose 2′-oxygen, making it distinct from adenine-base methylation. A 2024 stable isotope-diluted UHPLC–MS/MS study supports sensitive analysis of methylated purine nucleosides, but does not establish specific biological effects for this compound.
-
EDC.HCl: Practical Coupling Workflow and QC
2026-09-27
EDC.HCl activates carboxyl groups for amide-bond formation with primary amines in peptide synthesis and bioconjugation workflows. This guide covers handling and reaction setup for in vitro research; the supplied dossier reports no in vivo or clinical data.
-
CRISPRa Reveals Splice Effects in Accessible Cells
2026-09-26
Terkelsen and colleagues used CRISPR activation to induce disease-gene expression in patient-derived skin fibroblasts, enabling splice analysis for genes normally expressed in less accessible tissues. Their proof-of-principle study shows how targeted gene induction can extend RNA diagnostics while highlighting the need to validate results in the context of each gene and variant.